SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biao luo who wrote (214)12/16/1997 9:15:00 AM
From: r. peter Dale  Read Replies (1) of 4474
 
The dimerizing activity of AP1510 was higher than FK1012 in a variety of settings even though its affinity for FKBP was 25-50X lower. This suggests activity towards hFKBP is relatively low. They also indicate they're working on 2nd gen. mols. which binds exclusively to the FKBP fusion protein.

Peter

Note:
The fact that rapamycin is immunosuppressive v/v hFKBP/FRAP as well is acknowledged but not addressed in the JCI paper. They are modifying their constructs to interact with a nonimmunosuppressive rapamycin analogue (successful approach with the cyclosporin-cyclophilin complex).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News